Stocks and Investing
Stocks and Investing
Thu, May 30, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jason Gerberry Maintained (TEVA) at Strong Buy with Increased Target to $21 on, May 30th, 2024
Jason Gerberry of B of A Securities, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Strong Buy with Increased Target from $18 to $21 on, May 30th, 2024.
Jason has made no other calls on TEVA in the last 4 months.
There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Chris Schott of "JP Morgan" Upgraded from Sell to Hold and Held Target at $14 on, Friday, March 8th, 2024
- Nathan Rich of "Goldman Sachs" Maintained at Hold with Increased Target to $11 on, Monday, February 5th, 2024
These are the ratings of the 2 analyists that currently disagree with Jason
- David Amsellem of "Piper Sandler" Reiterated at Buy with Increased Target to $20 on, Monday, May 13th, 2024
- Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $20 on, Thursday, May 9th, 2024
Contributing Sources